Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications
Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.